Summary
Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (hazard ratio, 0.60; 95% CI, 0.37-0.97). This association remained significant after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29-0.92). These findings suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic malignancy and COVID-19.
Competing Interest Statement
Michael A. Thompson reports Travel support from Syapse, Royalties from UpToDate, Connect MDS/AML Registry in Celgene, Myeloma Registry in Takeda; Stock ownership in Doximity; personal fees from VIA Oncology, Adaptive Advisory Board, and GSK. Dr. Thompson is the Local PI for Clinical Trials in AbbVie, BMS, CRAB CTC, Denovo, Research Network, Eli Lilly, LynxBio, Strata Oncology, TG Therapeutics; all outside the submitted work. Jeffrey P. Henderson reports grant from the Longer Life Foundation: an RGA/Washington University Partnership; and unrestricted financial gift from Octapharma USA, Inc. to his institution to support COVID research in his laboratory during the conduct of the study. Pankil K. Shah reports grants from BARDA during the conduct of the study. Michael J. Joyner reports grants from BARDA during the conduct of the study. Toni K. Choueiri reports Honoraria from Alexion Pharmaceutic support; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate; Consulting or Advisory Role from Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate; Research Funding from Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst) all outside the submitted work. Elizabeth A. Griffiths reports honoraria for advisory boards from Alexion Pharmaceuticals, Celgene/Bristol-Myers Squibb, AbbVie, and Novartis; and institutional research funding from Astex/Otsuka, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Celgene/Bristol-Myers Squibb, Celldex Therapeutics, and Genentech. Vadim S. Koshkin reports personal fees from Pfizer, Janssen, Dendrreon, AstraZeneca, Seattle Genetics, Clovis; grants from Nektar, Novartis / Endocyte, Janssen, Clovis, Prostate Cancer Foundation; all outside the submitted work. Elizabeth Wulff-Burchfield reports personal fees from Astellas, Bristol Myers Squibb (BMS); grants from Pfizer Global Medical Grants; Advisory board membership in Exelixis; stock ownership by a family member in Nektar and Immunomedics; all outside the submitted work. Dimpy P. Shah reports grants from BARDA, the American Cancer Society and Hope Foundation for Cancer Research during the conduct of the study. Jeremy L. Warner reports grants from National Cancer Institute, during the conduct of the study; personal fees from Westat, IBM Watson Health, and HemOnc.org LLC; all outside the submitted work. Samuel Rubinstein, Daniel Flora, Anthony P. Gulati, Clara Hwang, Esperanza B. Papadopoulos, Elizabeth V. Robilotti, Christopher T. Su, Zhuoer Xie, Peter Paul Yu, Sanjay Mishra, and Jonathon W. Senefeld have nothing to disclose.
Clinical Trial
NCT04354701
Funding Statement
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096; National Cancer Institute (NCI) grants P30 CA008748, P30 CA046592, P30 CA054174, P30 CA068485, T32 CA236621, and U01 CA231840; National Center for Advancing Translational Sciences (NCATS) grant UL1 TR002377; Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors); United Health Group; National Basketball Association (NBA); Millennium Pharmaceuticals; Octapharma USA, Inc; the American Cancer Society and Hope Foundation for Cancer Research grant MRSG-16-152-01-CCE; the Longer Life Foundation: A RGA/Washington University Partnership; and the Mayo Clinic. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB exemption was determined by the Vanderbilt University IRB, #200467
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The full CCC19 data dictionary and R code to generate the derived variables is publicly available on GitHub. The data used for the analyses will be made available in aggregate form through a dashboard on the ccc19.org website, six months from the peer-reviewed publication of this research.
